Physician profile
Pascal E Spehar
NPI 1790738300
$2,503.43
in general payments reported to CMS, 2019-2025
26 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,012 · 2020: $56.33 · 2021: $72.54 · 2022: $146 · 2023: $89.83 · 2024: $1,015 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716 · Travel and Lodging: $491 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.46 |
| Travel and Lodging | $491.28 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,205.41 | 2019-2024 | |
| Medical Device Business Services, INC. | $461.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.33 | 2022-2025 | |
| Integra Lifesciences Corporation | $124.47 | 2019 | |
| Ethicon US, LLC | $85.21 | 2019-2020 | |
| Taiho Oncology, INC. | $46.67 | 2024-2025 | |
| Janssen Biotech, INC. | $44.07 | 2024-2025 | Rybrevant, Tecvayli |
| Smith+Nephew, INC. | $39.86 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $37.32 | 2023-2024 | Libtayo |
| Melinta Therapeutics, LLC | $35.80 | 2019 | |
| Puma Biotechnology, INC. | $34.84 | 2022 | |
| Baxter Healthcare | $28.20 | 2023 | Tisseel |
| Acell, INC. | $20.60 | 2019 | |
| Sirtex Medical INC | $20.58 | 2024 | Sir-Spheres Microspheres |
| Daiichi Sankyo INC. | $20.05 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $18.49 | 2019 | |
| Merck Sharp & Dohme LLC | $18.32 | 2021 | |
| Global Blood Therapeutics, INC. | $18.21 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.05 | 2025 | Monoferric |
| Innocoll Pharmaceuticals Limited | $16.51 | 2022 | |
| Genentech USA, INC. | $14.84 | 2025 | Venclexta |
| Pfizer INC. | $14.56 | 2020 | |
| Seagen INC. | $14.27 | 2021 | |
| Dilon Technologies, INC. | $13.64 | 2025 | Hemoblast Bellows |
| Olympus America INC. | $12.37 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Spehar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.